Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section

ConditionsPost Partum Haemorrhage Cesarean Section Surgery

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexFemale

Age18-45

SponsorPak Emirates Military Hospital

About this trial

To determine the effectiveness of prophylactic intravenous calcium chloride administered after cord clamping in reducing postpartum blood loss during intrapartum cesarean section.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Women aged 18-45 years undergoing intrapartum cesarean section at ≥34 weeks of gestation.

Exposure to oxytocin during labor before CS.

Singleton pregnancy with no known fetal anomalies.

Disqualifiers

Known bleeding disorders or preoperative coagulation abnormalities

Preeclampsia or hypertensive disorders contraindicate calcium use.

History of cardiac disease or arrhythmias

Placental abnormalities, i.e., placenta previa, accreta

Trial design

Design model

Parallel

Treatments tested in this trial

Calcium Chloride
Drug
Group A will receive 1 g of intravenous calcium chloride diluted in 100 mL of normal saline, administered over 10 minutes beginning one minute after cord clamping, in addition to standard oxytocin therapy (10 IU intravenous bolus followed by 20 IU infusion).
Placebo
Other intervention
Group B will receive standard care with oxytocin alone.

Treatment groups

182 Participants

are divided into 2 treatment groups

Group A: Group AExperimental treatment 1 intervention

Group B: Group BPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Blood Loss

Quantitative blood loss will be calculated using the gravimetric method. All surgical swabs, drapes, and pads will be weighed immediately after use, and their pre-determined dry weights will be subtracted to obtain the net blood loss, with the assumption that 1 g of weight gain is equivalent to 1 mL of blood. Blood collected in suction containers will also be measured. Adjustment for amniotic fluid will be made by recording the volume of clear amniotic fluid suctioned immediately after uterine incision and before placental delivery, which will then be subtracted from the total suction volume. Each weighed item and suction measurement will be labeled sequentially according to the patient's study ID at the time of surgery.

Time frame

24 hours

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pak Emirates Military Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: